A Study on the Epidemiology of COVID-19-Related Guillain-Barré Syndrome in the United States.

Q3 Medicine

Journal of Clinical Neuromuscular Disease Pub Date : 2024-06-01 DOI:10.1097/CND.0000000000000480

Aditya Sharma, Aditi Sharma, Ayman O Soubani

{"title":"A Study on the Epidemiology of COVID-19-Related Guillain-Barré Syndrome in the United States.","authors":"Aditya Sharma, Aditi Sharma, Ayman O Soubani","doi":"10.1097/CND.0000000000000480","DOIUrl":null,"url":null,"abstract":"Introduction: Several neurological complications have been reported with COVID-19, including Guillain-Barré syndrome (GBS). We looked at incidence, baseline characteristics, and in-hospital outcomes of COVID-19-associated GBS in the United States.Study design and methods: We conducted a retrospective analysis using the US National Inpatient Sample database to identify hospitalizations for COVID-19 and GBS, using International Classification of Disease, 10th Revision, codes G610 and G650 for GBS and U071 for COVID-19. The codes used in this study are listed in Supplemental Digital Content 1 (see e Appendix, http://links.lww.com/JCND/A69).Results: In total, 13,705 GBS admissions were recorded nationwide in 2020; of these, 1155 (8.43%) were associated with COVID-19. The frequency of GBS in COVID-19 admissions was 0.07%, compared with 0.08% in non-COVID-19 admissions (P = 0.8166). COVID-19 cohort with GBS had higher utilization of invasive mechanical ventilation (20.8% vs. 11.8%, P < 0.001) in comparison with COVID-19 cohort without GBS. GBS admissions with COVID-19 exhibited significantly higher inpatient mortality (12.2% vs. 3%, P < 0.001) compared with GBS admissions without COVID-19.Interpretation: Our findings underscore GBS as a rare yet severe complication of COVID-19, highlighting a significant difference in mortality when compared with GBS not associated with COVID-19.","PeriodicalId":39645,"journal":{"name":"Journal of Clinical Neuromuscular Disease","volume":"25 4","pages":"178-183"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Neuromuscular Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CND.0000000000000480","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Several neurological complications have been reported with COVID-19, including Guillain-Barré syndrome (GBS). We looked at incidence, baseline characteristics, and in-hospital outcomes of COVID-19-associated GBS in the United States.

Study design and methods: We conducted a retrospective analysis using the US National Inpatient Sample database to identify hospitalizations for COVID-19 and GBS, using International Classification of Disease, 10th Revision, codes G610 and G650 for GBS and U071 for COVID-19. The codes used in this study are listed in Supplemental Digital Content 1 (see e Appendix, http://links.lww.com/JCND/A69).

Results: In total, 13,705 GBS admissions were recorded nationwide in 2020; of these, 1155 (8.43%) were associated with COVID-19. The frequency of GBS in COVID-19 admissions was 0.07%, compared with 0.08% in non-COVID-19 admissions (P = 0.8166). COVID-19 cohort with GBS had higher utilization of invasive mechanical ventilation (20.8% vs. 11.8%, P < 0.001) in comparison with COVID-19 cohort without GBS. GBS admissions with COVID-19 exhibited significantly higher inpatient mortality (12.2% vs. 3%, P < 0.001) compared with GBS admissions without COVID-19.

Interpretation: Our findings underscore GBS as a rare yet severe complication of COVID-19, highlighting a significant difference in mortality when compared with GBS not associated with COVID-19.

查看原文本刊更多论文

美国 COVID-19 相关格林-巴利综合征流行病学研究》。

简介据报道，COVID-19可引起多种神经系统并发症，包括吉兰-巴雷综合征（GBS）。我们调查了美国 COVID-19 相关 GBS 的发病率、基线特征和住院结果：我们使用美国全国住院病人抽样数据库进行了一项回顾性分析，以确定 COVID-19 和 GBS 的住院情况，GBS 使用《国际疾病分类》第 10 次修订版中的代码 G610 和 G650，COVID-19 使用 U071。本研究使用的代码列于补充数字内容 1（见电子附录，http://links.lww.com/JCND/A69）。结果：2020年全国共记录了13705例GBS入院病例，其中1155例（8.43%）与COVID-19有关。COVID-19 入院患者中 GBS 的发生率为 0.07%，而非 COVID-19 入院患者中 GBS 的发生率为 0.08%（P = 0.8166）。与未患 GBS 的 COVID-19 入院患者相比，患 GBS 的 COVID-19 入院患者使用有创机械通气的比例更高（20.8% 对 11.8%，P < 0.001）。与无COVID-19的GBS住院患者相比，COVID-19的GBS住院患者死亡率明显更高（12.2% vs. 3%，P < 0.001）：我们的研究结果表明，GBS 是 COVID-19 罕见但严重的并发症，与 COVID-19 无关的 GBS 相比，死亡率差异显著。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Neuromuscular Disease Medicine-Medicine (all)

CiteScore

1.60

自引率

0.00%

发文量

期刊介绍： Journal of Clinical Neuromuscular Disease provides original articles of interest to physicians who treat patients with neuromuscular diseases, including disorders of the motor neuron, peripheral nerves, neuromuscular junction, muscle, and autonomic nervous system. Each issue highlights the most advanced and successful approaches to diagnosis, functional assessment, surgical intervention, pharmacologic treatment, rehabilitation, and more.